{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:40:33Z","timestamp":1790678433604,"version":"4.1.0"},"reference-count":30,"publisher":"Society of Nuclear Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.2967\/jnumed.121.263323","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T22:35:16Z","timestamp":1642113316000},"page":"1364-1370","source":"Crossref","is-referenced-by-count":41,"title":["Substitution of l-Tryptophan by <b>\u03b1<\/b>-Methyl-l-Tryptophan in <sup>177<\/sup>Lu-RM2 Results in <sup>177<\/sup>Lu-AMTG, a High-Affinity Gastrin-Releasing Peptide Receptor Ligand with Improved In\u00a0Vivo Stability"],"prefix":"10.2967","volume":"63","author":[{"given":"Thomas","family":"G\u00fcnther","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Deiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Felber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roswitha","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00fcrgen","family":"Wester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"2022090212401070000_63.9.1364.1","first-page":"e3986","article-title":"Neuroendocrine tumor therapy with lutetium-177: a literature review","volume":"11","author":"Maqsood","year":"2019","journal-title":"Cureus."},{"key":"2022090212401070000_63.9.1364.2","doi-asserted-by":"crossref","first-page":"1536012118776068","DOI":"10.1177\/1536012118776068","article-title":"PSMA theranostics: current status and future directions","volume":"17","author":"Rahbar","year":"2018","journal-title":"Mol Imaging."},{"key":"2022090212401070000_63.9.1364.3","first-page":"1139","article-title":"Bombesin receptor subtypes in human cancers: detection with the universal radioligand 125I-[D-TYR6, beta-ALA11, PHE13, NLE14] bombesin(6-14)","volume":"8","author":"Reubi","year":"2002","journal-title":"Clin Cancer Res."},{"key":"2022090212401070000_63.9.1364.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-002-0794-5"},{"key":"2022090212401070000_63.9.1364.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.259630"},{"key":"2022090212401070000_63.9.1364.6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.160739"},{"key":"2022090212401070000_63.9.1364.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.188011"},{"key":"2022090212401070000_63.9.1364.8","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/RLU.0000000000002209","article-title":"68Ga-NOTA-RM26 PET\/CT in the evaluation of breast cancer: a pilot prospective study","volume":"43","author":"Zang","year":"2018","journal-title":"Clin Nucl Med."},{"key":"2022090212401070000_63.9.1364.9","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.7150\/thno.14958","article-title":"Gastrin-releasing peptide receptor imaging in breast cancer using the receptor antagonist 68Ga-RM2 and PET","volume":"6","author":"Stoykow","year":"2016","journal-title":"Theranostics."},{"key":"2022090212401070000_63.9.1364.10","unstructured":"68-Ga-RM2 PET\/MRI in imaging patients with estrogen receptor-positive breast cancer. https:\/\/ClinicalTrials.gov\/show\/NCT03831711. ClinicalTrials.gov website. Published February 6, 2019. Updated December 13, 2021. Accessed June 9, 2022."},{"key":"2022090212401070000_63.9.1364.11","unstructured":"68Ga-RM2 PET\/CT in detecting regional nodal and distant metastases in patients with intermediate or high-risk prostate cancer. ClinicalTrials.gov website. https:\/\/ClinicalTrials.gov\/show\/NCT03113617. Published April 13, 2017. Updated December 7, 2020. Accessed June 9, 2022."},{"key":"2022090212401070000_63.9.1364.12","unstructured":"68Ga-RM2 PET\/MRI in biochemically recurrent prostate cancer. ClinicalTrials.gov website. https:\/\/ClinicalTrials.gov\/show\/NCT02624518. Published December 8, 2015. Updated May 3, 2022. Accessed June 9, 2022."},{"key":"2022090212401070000_63.9.1364.13","unstructured":"177Lu-NeoB in patients with advanced solid tumors and with 68Ga-NeoB lesion uptake. ClinicalTrials.gov website. https:\/\/ClinicalTrials.gov\/show\/NCT03872778. Published March 13, 2019. Updated February 3, 2022. Accessed June 9, 2022."},{"key":"2022090212401070000_63.9.1364.14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00259-019-04504-3","article-title":"First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer","volume":"47","author":"Kurth","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022090212401070000_63.9.1364.15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.23.10662"},{"key":"2022090212401070000_63.9.1364.16","doi-asserted-by":"publisher","DOI":"10.1021\/bc9000189"},{"key":"2022090212401070000_63.9.1364.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.114082"},{"key":"2022090212401070000_63.9.1364.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1596-9"},{"key":"2022090212401070000_63.9.1364.19","doi-asserted-by":"crossref","unstructured":"Kaloudi A Lymperis E Giarika A . NeoBOMB1, a GRPR-antagonist for breast cancer theragnostics: first results of a preclinical study with [67Ga]NeoBOMB1 in T-47D cells and tumor-bearing mice. Molecules. 2017;22:1950.","DOI":"10.3390\/molecules22111950"},{"key":"2022090212401070000_63.9.1364.20","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1021\/acsomega.8b03293","article-title":"Positron emission tomography imaging of the gastrin-releasing peptide receptor with a novel bombesin analogue","volume":"4","author":"Lau","year":"2019","journal-title":"ACS Omega."},{"key":"2022090212401070000_63.9.1364.21","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s11307-018-1185-z","article-title":"In vivo stabilized SB3, an attractive GRPR antagonist, for pre- and intra-operative imaging for prostate cancer","volume":"20","author":"Bakker","year":"2018","journal-title":"Mol Imaging Biol."},{"key":"2022090212401070000_63.9.1364.22","doi-asserted-by":"crossref","first-page":"6873684","DOI":"10.1155\/2017\/6873684","article-title":"High contrast PET imaging of GRPR expression in prostate cancer using cobalt-labeled bombesin antagonist RM26","volume":"2017","author":"Mitran","year":"2017","journal-title":"Contrast Media Mol Imaging."},{"key":"2022090212401070000_63.9.1364.23","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-014-0063-1"},{"key":"2022090212401070000_63.9.1364.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2004.11.003"},{"key":"2022090212401070000_63.9.1364.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.176636"},{"key":"2022090212401070000_63.9.1364.26","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.nucmedbio.2014.12.009","article-title":"The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26","volume":"42","author":"Varasteh","year":"2015","journal-title":"Nucl Med Biol."},{"key":"2022090212401070000_63.9.1364.27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.nucmedbio.2016.11.004","article-title":"Approaches to improve metabolic stability of a statine-based GRP receptor antagonist","volume":"45","author":"Popp","year":"2017","journal-title":"Nucl Med Biol."},{"key":"2022090212401070000_63.9.1364.28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-3145"},{"key":"2022090212401070000_63.9.1364.29","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-006-0347-4"},{"key":"2022090212401070000_63.9.1364.30","doi-asserted-by":"publisher","DOI":"10.1667\/RR3021"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.121.263323","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T19:47:21Z","timestamp":1662148041000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.121.263323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,1]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.2967\/jnumed.121.263323"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.121.263323","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,13]]}}}